{"count": 2, "results": [{"_id": "28464864", "pmid": 28464864, "pmcid": "PMC5414226", "title": "Metformin produces growth inhibitory effects in combination with nutlin-3a on malignant mesothelioma through a cross-talk between mTOR and p53 pathways", "journal": "BMC Cancer", "authors": ["Shimazu K", "Tada Y", "Morinaga T", "Shingyoji M", "Sekine I", "Shimada H", "Hiroshima K", "Namiki T", "Tatsumi K", "Tagawa M"], "date": "2017-05-02T00:00:00Z", "doi": "10.1186/s12885-017-3300-y", "meta_date_publication": "2017 May 2", "meta_volume": "17", "meta_issue": "1", "meta_pages": "309", "score": 50094.05, "text_hl": "Nevertheless, an effect of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ has not yet been examined in @<m>DISEASE_Mesothelioma</m> @DISEASE_MESH:D008654 @@@mesothelioma@@@.", "citations": {"NLM": "Shimazu K, Tada Y, Morinaga T, Shingyoji M, Sekine I, Shimada H, Hiroshima K, Namiki T, Tatsumi K, Tagawa M. Metformin produces growth inhibitory effects in combination with nutlin-3a on malignant mesothelioma through a cross-talk between mTOR and p53 pathways BMC Cancer. 2017 May 2;17(1):309. PMID: 28464864", "BibTeX": "@article{28464864, title={Metformin produces growth inhibitory effects in combination with nutlin-3a on malignant mesothelioma through a cross-talk between mTOR and p53 pathways}, author={Shimazu K and Tada Y and Morinaga T and Shingyoji M and Sekine I and Shimada H and Hiroshima K and Namiki T and Tatsumi K and Tagawa M}, journal={BMC Cancer}, volume={17}, number={1}, pages={309}}"}}, {"_id": "27565939", "pmid": 27565939, "title": "Metformin and survival of people with type 2 diabetes and pleural mesothelioma: A population-based retrospective cohort study.", "journal": "Lung Cancer", "authors": ["Wu H", "Walker J", "Damhuis RA", "Brewster DH", "Wild SH", "Scottish Diabetes Research Network Epidemiology Group"], "date": "2016-09-01T00:00:00Z", "doi": "10.1016/j.lungcan.2016.07.020", "meta_date_publication": "2016 Sep", "meta_volume": "99", "meta_issue": "", "meta_pages": "194-9", "score": 50057.07, "text_hl": "Similar non-statistically significant associations were obtained in sensitivity analyses based on @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ use in year prior to diagnosis of @<m>DISEASE_Mesothelioma</m> @DISEASE_MESH:D008654 @@@mesothelioma@@@, use of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ for more than one year, in people below the mean age at diagnosis of @<m>DISEASE_Mesothelioma</m> @DISEASE_MESH:D008654 @@@mesothelioma@@@ (74 years) and 74 years of age or older, limitation to @DISEASE_Mesothelioma_Malignant @DISEASE_MESH:D000086002 @@@pleural mesothelioma@@@ and following further adjustment for body mass index and smoking. ", "citations": {"NLM": "Wu H, Walker J, Damhuis RA, Brewster DH, Wild SH, Scottish Diabetes Research Network Epidemiology Group. Metformin and survival of people with type 2 diabetes and pleural mesothelioma: A population-based retrospective cohort study. Lung Cancer. 2016 Sep;99():194-9. PMID: 27565939", "BibTeX": "@article{27565939, title={Metformin and survival of people with type 2 diabetes and pleural mesothelioma: A population-based retrospective cohort study.}, author={Wu H and Walker J and Damhuis RA and Brewster DH and Wild SH and Scottish Diabetes Research Network Epidemiology Group}, journal={Lung Cancer}, volume={99}, pages={194-9}}"}}]}